Erratum to: Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients

Abstract Background It is still controversial that the efficacy of nucleot(s)ide analogs (NAs) and pegylated interferon (PegIFN) combination therapy for hepatitis B e antigen positive (HBeAg +) patients. It was assessed whether PegIFN and entecavir (ETV) combination therapy could bring more benefit for HBeAg + patients. Methods The treatment naïve HBeAg + patients initiated with PegIFN alfa-2a (PegIFNα-2a) for 24 weeks without early response (early response: HBsAg < 1500 IU/mL and HBV DNA < 10 5 copies/mL) were recruited in the current study. Among total of 94 patients, 51 were continued with PegIFNα-2a monotherapy, 43 were offered PegIFNα-2a and ETV combined therapy. Results It was demonstrated that better outcomes in response to the combined therapy compared to that of the monotherapy, including more HBsAg decline and loss, HBV DNA decline and HBeAg clearance. Importantly, the patients with HBsAg levels between 1500 - 20,000 IU/mL initially or between 5000 - 20000 IU/mL after 24 weeks of PegIFNα-2a were more benefit from the combined therapy, compared to that of monotherapy. Conclusions The combined therapy of PegIFNα-2a and ETV is more efficacy for HBeAg + patients without early response to PegIFN monotherapy, and the HBsAg levels are a good predictor of the treatment outcomes.

Download Full-text

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders

Journal of Hepatology ◽

10.1016/s0168-8278(03)00076-x ◽

2003 ◽

Vol 38 (6) ◽

pp. 818-826 ◽

Cited By ~ 85

Author(s):

Eugene R Schiff ◽

Jules L Dienstag ◽

Selim Karayalcin ◽

Ian S Grimm ◽

Robert P Perrillo ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Combination Therapy ◽

Chronic Hepatitis B ◽

Hepatitis B E Antigen ◽

Positive Chronic Hepatitis

Download Full-text

Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00249-15 ◽

2015 ◽

Vol 59 (7) ◽

pp. 4121-4128 ◽

Cited By ~ 31

Author(s):

Guo-Jun Li ◽

Yi-Qi Yu ◽

Shao-Long Chen ◽

Ping Fan ◽

Ling-Yun Shao ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Combination Therapy ◽

Therapy Group ◽

Hepatitis B Surface Antigen ◽

Hbeag Seroconversion ◽

Pegylated Interferon ◽

Hepatitis B E Antigen ◽

Sequential Combination

ABSTRACTNucleos(t)ide analogues rarely result in a durable off-treatment response in chronic hepatitis B infection, whereas pegylated interferon (Peg-IFN) induces a long-lasting response only in a subset of patients. We assessed the effect of sequential combination therapy with Peg-IFN-α2a and entecavir in hepatitis B e antigen (HBeAg)-positive patients with prior long-term entecavir therapy and investigated the predictors of response to treatment. HBeAg-positive individuals who did not achieve HBeAg seroconversion during previous long-term entecavir therapy, receiving Peg-IFN-α2a added to ongoing entecavir therapy (sequential combination [S-C] therapy;n= 81) for 48 weeks or remaining on entecavir monotherapy (n= 116), were retrospectively included. A matched pair was created at a 1:1 ratio from each treatment group. The primary endpoint was HBeAg seroconversion at week 48. Subgroup analysis of response prediction was conducted for 81 patients with S-C therapy. More patients in the S-C therapy group achieved HBeAg seroconversion than those in the entecavir group (44% versus 6%;P< 0.0001). An HBeAg level of <200 signal-to-cutoff ratio (S/CO) at baseline was a strong predictor for higher HBeAg seroconversion than that achieved when HBeAg was ≥200 S/CO (64.2% versus 17.9%;P< 0.0001). Hepatitis B surface antigen (HBsAg) levels at baseline and the decrease in HBsAg levels predicted HBsAg loss in the S-C therapy group. The combination of baseline HBeAg of <200 S/CO and HBsAg of <1,000 IU/ml and an HBsAg decline at week 12 of ≥0.5 log10IU/ml provided the highest rate of HBeAg seroconversion (92.31%) and HBsAg loss (83.3%) at week 48. Patients receiving sequential combination therapy have a higher rate of HBeAg seroconversion and are more likely to experience HBsAg clearance than do those continuing entecavir monotherapy. Sequential combination therapy can be guided by baseline HBsAg/HBeAg levels and on-treatment HBsAg dynamics.

Download Full-text